



Serological Response to Measles Revaccination in a Small Population After a Mass Measles Revaccination Program

Fariba Shirvani^{1,3*}, Parviz Tabatabaee², Reza Shiari^{1,3}, Farideh Shiwa^{1,3}, Mohamad Hossein Soltanzadeh¹

¹ Department of Pediatrics, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

² Department of Pediatrics, Tehran University of Medical Sciences, Tehran, IR Iran

³ Pediatric Infectious Research Center (PIRC), Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

ARTICLE INFO

Article type:
Original Article

Article history:
Received: 10 Sep 2011
Revised: 30 Sep 2011
Accepted: 10 Oct 2011

Keywords:
Measles
Immunization
Immunoglobulin M

ABSTRACT

Background: In spite of vaccination, outbreaks of measles occur in many countries, and measles remains the most frequent cause of death among vaccine preventable diseases. **Objectives:** To compare anti-measles antibody titer between revaccinated and non-revaccinated medical students 2 years after the National MR (Measles, Rubella) Vaccination Program, which was implemented in 2002-2003 for individuals aged 5 to 25 years in Iran. **Patients and Methods:** This stratified cross-sectional study was conducted on 78 revaccinated and unvaccinated for national MMR vaccination (2002) medical students aged 22-25 years, who attended our Markaz Tebi Children Hospital in Tehran for their pediatric rotation from summer to winter in 2005. The revaccinated group was selected by simple random sampling from a list of names of the students and the non-revaccinated group included all the non-revaccinated students. Serum IgG and IgM anti-measles antibody titers of the subjects were measured using indirect enzyme-linked immunosorbent assay (ELISA), and the levels were compared between the 2 groups of students. Data were analyzed using chi square test and independent samples *t* test. Statistical significance was defined as *P* values of < 0.05 by SPSS ver.13 Software. **Results:** Overall, we recruited 45 subjects with a mean age of 23.7 ± 0.12 years in the revaccinated group and 33 subjects with a mean age of 24 ± 0.25 years in the non-revaccinated group ($P = 0.2$). The mean anti-measles IgG antibody titer was 31.8 ± 21.2 IU/mL (range, 1-190 IU/mL) in the revaccinated group and 6.12 ± 8.8 IU/mL (range, 1-45 IU/mL) in the non-revaccinated group ($P < 0.001$). The mean anti-measles IgM antibody titers were 2.6 ± 6.7 IU/mL (range, 1-45 IU/mL) and 1 ± 0 IU/mL (range, 0-1 IU/mL) in the revaccinated and non-revaccinated groups, respectively ($P = 0.1$). Anti-measles IgG was present (serum titer ≥ 13 IU/mL) in 46.7% of the individuals of the revaccinated group and 6% of the individuals of the non-revaccinated group ($P < 0.001$). **Conclusions:** The results of this study indicate that although the percentage of individuals with protective levels of anti-measles antibody increased to 46.7% after revaccination, the protection was inadequate in more than 50% of vaccine recipients, thereby, emphasizing the need for checking antibody levels after revaccination.

Published by Kowsar Corp, 2012. cc 3.0.

► Implication for health policy/practice/research/medical education:

This study which is done on medical students in Tehran after measles national vaccination campaign notes the importance of measles antibody status screening in our society.

* Corresponding author: Fariba Shirvani, Pediatric Infections Research Center (PIRC), Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Shariati St., P.O Box: 15468-15514, Tehran, IR Iran. Tel/Fax: +98-2122226941, E-mail: fariba_shirvani@yahoo.com

DOI: 10.5812/jcp.7144

© 2012 Iranian Society of Pediatrics; Published by Kowsar Corp.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

► Please cite this paper as:

Shirvani F, Tabatabaee P, Shiari R, Shiwa F, Soltanzadeh MH. Serological Response to Measles Revaccination in a Small Population After a Mass Measles Revaccination Program. *J Compr Ped.* 2012;3(1):7-11. DOI: 10.5812/jcp.7144

1. Background

Measles is a highly infectious disease that may well be eradicated because of its low genetic variation and inability to manifest as a subclinical disease in human beings. The mortality rate associated with measles is highly dependent on the nutritional status of the populace and may vary from 1% to 30% in different communities. Patients with measles may show serious complications, such as blindness. The World Health Organization (WHO) reports show that about 30,000,000 new cases of measles occur annually in developing countries and cause 300,000 deaths, accounting for 40% of the deaths caused by vaccine preventable diseases (1). The disease has been eliminated in many western countries by implementing aggressive strategies, including “catch-up” mass campaigns to vaccinate all children aged 1 to 14 years, “mop-up” campaigns for children who missed the “catch-up” campaign, efficient routine vaccination services capable of reaching 90% of infants, strong surveillance activities, prompt outbreak response, and “follow-up” campaigns every 24 years that focus on 1-4 year-old children (2).

To control the outbreaks of the disease in our country, all individuals aged 5 to 25 years were revaccinated in a national campaign named “National Measles Rubella (MR) Vaccination Program” from December 22nd 2002 to January 5th 2003.

2. Objectives

The aim of this study was to compare the anti-measles antibody titers between revaccinated and non-revaccinated individuals 2 years after the national MR vaccination program.

3. Patients and Methods

This study was a stratified cross-sectional study conducted on healthy medical students who attended our hospital in Tehran from summer 2005 to winter 2005 for their pediatric rotation. The revaccinated group was randomly selected from a list of students who had undergone revaccination and the non-revaccinated group included all the non-revaccinated students. Subjects with a history of severe measles or any other infectious disease, fever, immunodeficiency, or any systemic disease such as heart failure or renal impairment were excluded in order to decrease the effect of confounding variables and determination the actual difference in antibody level between two groups.

Based on our assumption 10% of students were protected before Revaccinated, (Non published reports) and protection rate may reach at least 40% after revaccination

and number of cases in each group was calculated approximately 34 cases.

All subjects filled up a questionnaire that documented their age, sex, number of years of education, and history of skin rashes or any infectious disease.

Blood samples (5 mL of peripheral blood) were collected from all participants by their permission. Serum titers of anti-measles IgG and IgM antibodies were measured using an indirect enzyme-linked immunosorbent assay (ELISA) method with the IgG and IgM RF566 11 kit (IBL Company, Hamburg, Germany). After blood sampling, the serum was separated and stored in a refrigerator at -70 °C; 78 samples were collected. The samples were thawed at room temperature and tested with ELISA at 25 °C. Each serum sample was diluted to the strength of 1:101 in a standard buffer solution and added to the 4 standard wells A, B, C, and D (e.g. A1, B1, C1, and D1 for specimen number 1). After incubation at 25 °C for 60 min, the wells were emptied and rinsed thrice with 0.3 mL of buffer, and then the plates were dried by inverting them on an absorbent material. Then, 0.1 mL of secondary conjugated enzyme was added to each well. After a 30-min incubation at 25 °C, the wells were emptied, rinsed, and dried again as mentioned above. Then, 0.1 mL of Chromogen (TMP) solution was added to each well and after incubation at room temperature for 20 min, 0.1 mL of stopping solution was added and optical density (OD) was measured at 450 nm with an ELISA reader, (model ICN MS212) (Tecon) Switzerland. IgG and IgM titers were estimated using a standard curve of logarithmic OD values.

Data were analyzed using chi square test and independent samples *t* test. Statistical significance was defined as $P < 0.05$. We used SPSS ver.13 software for data analysis.

There was no other limitations for the study.

4. Results

The study was performed on 78 persons, of which 45 subjects with the mean age of 23.8 ± 0.8 years had been revaccinated. The mean age of the non-revaccinated group was 24.0 ± 1.5 years ($P = 0.2$). The revaccinated group included 29 women (64.4%) and 16 men, (35.6%) and the non-revaccinated group was composed of 19 women (57.6%) and 14 men (42.4%) ($P = 0.544$).

There was no intergroup significant difference in the measles vaccination and disease history ($P = 0.6$ and $P = 0.7$).

Table 1 shows two baseline variables such as age, gender, number of children in family, mother occupational status, father's occupation as physician. As it is seen number of children in family is higher in non-revaccinated and occupation of father as a physician in higher in revacci-

nated group, although these variables have no effect on antibody levels in students.

The mean anti-measles IgG titer was 31.8 ± 21.2 IU/mL (95% CI = 25.6-38.0), (range, 1-190 IU/mL) in the revaccinated group and 6.12 ± 8.8 IU/mL (95% CI = 3.1-9.1) (range, 1-45 IU/mL) in the non-revaccinated group ($P = 0.004$). The mean anti-measles IgM titer was 2.6 ± 6.7 IU/mL (95% CI = 0.6-4.6), (range, 1-45 IU/mL) in the revaccinated group and 1.0 ± 0.0 IU/mL (range, 0-1 IU/mL) in the non-revaccinated group ($P = 0.1$).

The results of anti-measles IgG titer assessments were classified into 3 groups according to the detected levels of the antibody, viz. negative (≤ 7 IU/mL), undetermined (8-12 IU/mL), and positive (≥ 13 IU/mL); 46.7% individuals in the revaccinated group and 6% in the non-revaccinated

group were IgG positive ($P < 0.001$).

Table 2 summarizes the results of the IgG titer assessments for both groups according to this classification and Figure shows the distribution of individuals in both the groups on the basis of their serum IgG titers.

IgM measurements were also classified into 3 groups, but the values obtained were not significantly different between the 2 study groups (data are not presented).

5. Discussion

The global coverage of measles vaccination increased from 15% in 1980 to around 80% in 1990, resulting in a 95% reduction in death and 90% reduction in cases, in comparison with the pre-vaccination era obtained in 1995. However, actual figures vary in different countries. The




Figure. Diagram of Revaccinated and Non-Revaccinated Groups individual IgG Titer

Table 1. Distribution of Baseline Variables in Revaccinated and Non-Revaccinated Students

	Revaccinated, n = 16	Non-Revaccinated, n = 14	Significance
Male, No.	16/30	14/30	NS ^{a,b}
Age, y, Mean \pm SD	23.7 \pm 0.8	24 \pm 1.5	NS ^{a,c}
Number of children in family, mean \pm SD	3 \pm 1.4	3.6 \pm 1.6	0.04 ^c
Mother not occupied, %	55	53	NS ^{a,b}
Father is physician, %	31.1	12.4	0.04 ^b

^a Abbreviation: NS, non-significance

^b Independent *t* test

^c Chi-square test

Table 2. Distribution of Revaccinated and Non-Revaccinated Individuals on the Basis of Their IgG Titer

Groups	IgG Titer (IU/mL)			P value ^a	Mean \pm SD	Total, No. (%)	P value ^b
	Negative (≤ 7), No. (%)	Undetermined (8-12), No. (%)	Positive (≥ 13), No. (%)				
Non-revaccinated, IU/mL	24 (72.7)	7 (21.2)	2 (6.1)	< 0.001	6.12 \pm 8.8	33 (42.3)	< 0.001
Revaccinated, IU/mL	16 (35.6)	8 (17.8)	21 (46.7)	< 0.001	31.8 \pm 21.2	45 (57.7)	< 0.001
Total	40 (51.3)	15 (19.2)	23 (29.5)	-		78 (100.0)	-

^a Chi square test

^b Independent samples *t* test

global measles vaccination coverage increased rapidly up to the year 1990 but remained static at around 80% for most of the 1990s mainly because of low or even sometimes falling coverage rates in many developing countries, particularly in sub-Saharan Africa and the Middle East (2).

This feature, together with recurring localized outbreaks and epidemics of varying magnitude, promoted the health policy makers to plan new strategies such as mass vaccination campaigns. Immediately before the mass vaccination campaign in our country, measles antibody tests yielded negative results in 22.5% of Iranian soldiers (3). In an Ethiopian study in 1,928 children, aged 9 months to 5 years, 45% tested positive for measles antibody before the vaccination campaign and 85% tested positive after the campaign (4). According to initial reports, the mass vaccination campaign in Iran has been successful because new outbreaks of measles have been infrequent (5). Vaccine production in Iran was started by the Razi Institute in 1970, and the immunization program was launched in 1976 by the Ministry of health and health research institutes in Iran. In 1996, mass vaccination for measles control was performed for 7 million children before this can be omitted the mass campaign implemented in 2003, and a second dose of mumps, measles, rubella (MMR) vaccine has been added to the routine vaccination program since 2004. To date, we do not have a routine screening program for vaccine preventable diseases for health care workers (HCWs) and students. One study in 1981 showed low immunity levels among children aged below 3 years, and another study in 2000-2001 reported low antibody titers in children aged below 18 months, especially infants under 9 months of age (6, 7).

In 1997, a study conducted in Iran showed that out of 2,767 persons with eruptive disease with a clinical diagnosis of measles, 39% were confirmed to have measles according to a positive hemagglutination inhibition (HI) test while 61% had not been vaccinated against measles (8).

The immunity rate, as tested by antibody levels, in our country was around 73.3% in 2003, and this is a risk factor for serious measles epidemics (9). On the basis of an unpublished report, the number of suspicious measles cases in Iran can be estimated to be 11,605, and there were 1,096 confirmed cases of the disease in 2002; these figures decreased to 765 suspicious cases and 14 confirmed cases together with a 99% decrease in mortality rate in 2005 (10).

There are different approaches for antibody determination, such as antibody neutralization, ELISA, rapid dot-immunobinding assay, and detection of measles virus (MV) RNA by nested real-time PCR (11-13). Detection of viral antigenic variants helps in epidemiologic evaluation of the virus's entry into the community (14).

Identification of primary and secondary measles vaccine failure (i.e., failure to seroconvert after vaccination

and waning immunity after seroconversion, respectively) by measuring IgG avidity is very important for evaluating the success of measles control programs in developing countries (15).

In the present study, only 46.7% of revaccinated individuals had protective levels of the IgG antimeasles antibody, which is far from the optimal target that is assumed ideal for protection status in vaccinated students can be more than 80%. Although our study sample is not representative of our population, these findings may suggest the need for nationwide investigation or at least facilitate some local studies about primary and secondary measles vaccine failure in the community. The post-vaccination levels of anti-measles antibody varies with different factors, e.g., a study conducted in West Africa showed that anti-measles antibody concentration 5 to 7 years after vaccination was higher when checked in the rainy season than that in the dry season. Perhaps malaria and other infections cause fluctuations in antibody responses to vaccines and accelerate the decay of these responses (16). It is also known that subclinical infections can occur in patients with a previous history of vaccination because of the gradual decrease in the levels of specific antibodies to measles (secondary vaccine failure).

A large number of children in the UK are born to mothers with a history of measles vaccination and therefore, are susceptible to measles; if these children are exposed to the disease from international travelers, they are at a risk for contracting measles. Children in the US may have similar risks (17, 18). In conclusion, continuous monitoring of anti-measles antibody by an expert team is recommended in order to eliminate measles in our country.

Acknowledgments

We would like to thank Mr. Babak Akbari and Miss. Farzaneh Saboori and also all students who participated in this study.

Financial Disclosure

There is not any financial disclosure.

Funding/Support

This study is funded by Tehran University of Medical Sciences.

Author's Contribution

None declared.

References

1. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. *J Infect Dis.* 2001;**184**(7):817-26.
2. Omer MIA. Measles: a disease that has to be eradicated. *Ann Trop Paediatr.* 1999;**19**(2):125-34.
3. Ghorban G, Ahmadi K, Rajai M, Hosseinzadeh SM. [Antimeasles

- antibody status in Sepah Pasdaran soldiers (Tehran-Iran)]. *Majale Tebe Nezami*. 2003;**3**(5):177-81.
4. Nigatu W, Samuel D, Cohen B, Cumberland P, Lemma E, Brown DW, et al. Evaluation of a measles vaccine campaign in Ethiopia using oral-fluid antibody surveys. *Vaccine*. 2008;**26**(37):4769-74.
 5. Fars News Agency. [A report about communicable diseases in Iran]. Tehran; 2009.
 6. Nategh R, Ebrahimpour S. [Estimation of immunity to rubella in women 18 to 25 years old and children 2 to 12 years old in eastern Azerbaijan]. *Med J Tabriz Univ Med Scie*. 1986;**19**:27-39.
 7. Karimi A, Arjmandi A, Alborzi A, Rasouli M, Kadivar M. [Measles antibody in different age groups of children in shiraz (2000-2001)]. *Iran J Infect Dis Trop Med*. 2002;**7**(18):7-11.
 8. Mokhtari Azad T, Mahmoodi M, Hamkar R. [Epidemiologic features of measles in Iran]. *Hakim Res J*. 2000:19-26.
 9. Behjati M, Ayatollahi J, Karimi M, Tabatabaei F, Ghadiri A. [Epidemiologic feature of measles in Yazd province, 1995-96]. *Hakim Res J*. 2003;**6**:29-34.
 10. Ghorbani GH, Joneidi N, Ahmadi K. [Immunity situation of measles and its relation with education in soldiers of Iran Pasdaran Arm Forces in 2002-2003]. *Scientific and Research Journal of Islamic Republic of Iran Arm Forces*. 2003;**1**(4):227-30.
 11. Weigle KA, Murphy MD, Brunell PA. Enzyme-linked immunosorbent assay for evaluation of immunity to measles virus. *J Clin Microbiol*. 1984;**19**(3):376-9.
 12. van den Hof S, van Gageldonk-Lafeber AB, van Binnendijk RS, van Gageldonk PG, Berbers GA. Comparison of measles virus-specific antibody titres as measured by enzyme-linked immunosorbent assay and virus neutralisation assay. *Vaccine*. 2003;**21**(27-30):4210-4.
 13. Heberling RL, Kalter SS. Rapid dot-immunobinding assay on nitrocellulose for viral antibodies. *J Clin Microbiol*. 1986;**23**(1):109-13.
 14. Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. *Lancet*. 1999;**353**(9147):98-102.
 15. Pannuti CS, Morello RJ, Moraes JC, Curti SP, Afonso AM, Camargo MC, et al. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 Sao Paulo epidemic. *Clin Diagn Lab Immunol*. 2004;**11**(1):119-22.
 16. Tischer A, Santibanez S, Siedler A, Heider A, Hengel H. Laboratory investigations are indispensable to monitor the progress of measles elimination—results of the German Measles Sentinel 1999-2003. *J Clin Virol*. 2004;**31**(3):165-78.
 17. McQuillan GM, Kruszon-Moran D, Hyde TB, Forghani B, Bellini W, Dayan GH. Seroprevalence of measles antibody in the US population, 1999-2004. *J Infect Dis*. 2007;**196**(10):1459-64.
 18. Manikkavasagan G, Ramsay M. Protecting infants against measles in England and Wales: a review. *Arch Dis Child*. 2009;**94**(9):681-5.